Urine Microscopy and POCUS enthusiast
Mom of 2
Dabs in medical illustration, art and photography
T2d
Primary end-point #NephJC
Percentage of patients with at least 1 CV event: 🐟20.8% [127 pts] vs 🌽33.7% [208 pts]
Recurrent events: 🐟4.3% vs 🌽10.5%
🎣Holy Mackerel!
T2d
Primary end-point #NephJC
Percentage of patients with at least 1 CV event: 🐟20.8% [127 pts] vs 🌽33.7% [208 pts]
Recurrent events: 🐟4.3% vs 🌽10.5%
🎣Holy Mackerel!
T2h
Composite outcomes of the study favored fish oil. #NephJC
● Cardiac death: HR around 0.55.
● Myocardial infarction: about a 44% reduction.
● Peripheral vascular events leading to amputation: lower in the fish oil arm.
● Stroke: lowest hazard ratio of all outcomes, of around 0.37
T2h
Composite outcomes of the study favored fish oil. #NephJC
● Cardiac death: HR around 0.55.
● Myocardial infarction: about a 44% reduction.
● Peripheral vascular events leading to amputation: lower in the fish oil arm.
● Stroke: lowest hazard ratio of all outcomes, of around 0.37
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/38447639/
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/38447639/
Read the guideline: ja.ma/48hMMa2
Read the guideline: ja.ma/48hMMa2
Give me something clever to say 🤓
IgAN is no longer one-size-fits-all.
Timing matters.
Excitingly, tailored treatment is slowly becoming a reality.
@doctorgates.bsky.social
Give me something clever to say 🤓
IgAN is no longer one-size-fits-all.
Timing matters.
Excitingly, tailored treatment is slowly becoming a reality.
@doctorgates.bsky.social
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
Hi.
I'm the problem, it's me.
open.substack.com/pub/pulmccm/...
@thinkingcc.bsky.social @khaycock.bsky.social @drfreeze.bsky.social @maxhockstein.bsky.social @www.pulmccm.org
Hi.
I'm the problem, it's me.
open.substack.com/pub/pulmccm/...
@thinkingcc.bsky.social @khaycock.bsky.social @drfreeze.bsky.social @maxhockstein.bsky.social @www.pulmccm.org
Check out ✅ “IgAN: An Overview of the Clinical Trials” ca. 2025 from @kidneymed.bsky.social @alexgr23.bsky.social @saynanorouzi.bsky.social
#Nephpearls #NephSky #KidneyWk #IgAN
👉 pubmed.ncbi.nlm.nih.gov/41050133/
Check out ✅ “IgAN: An Overview of the Clinical Trials” ca. 2025 from @kidneymed.bsky.social @alexgr23.bsky.social @saynanorouzi.bsky.social
#Nephpearls #NephSky #KidneyWk #IgAN
👉 pubmed.ncbi.nlm.nih.gov/41050133/
FINEONE: finerenone in T1DM
ORIGIN: Atacicept (pronounced attack-e-sept) in IgAN (pronounced eye-gee-A-N)
Possible NEJM or Lancet simulpubs?
#KidneyWk
FINEONE: finerenone in T1DM
ORIGIN: Atacicept (pronounced attack-e-sept) in IgAN (pronounced eye-gee-A-N)
Possible NEJM or Lancet simulpubs?
#KidneyWk
FINEONE: finerenone in T1DM
ORIGIN: Atacicept (pronounced attack-e-sept) in IgAN (pronounced eye-gee-A-N)
Possible NEJM or Lancet simulpubs?
#KidneyWk
I need radiologists/techs to understand that
A. If I’ve signed the form, I know what I’m doing!
B. The risk of “contrast nephrotoxicity” is negligible, perhaps non-existent.
Read the lit!
I need radiologists/techs to understand that
A. If I’ve signed the form, I know what I’m doing!
B. The risk of “contrast nephrotoxicity” is negligible, perhaps non-existent.
Read the lit!
Some plants are nephrotoxic and can injure the kidneys.
📖 In Tropical Nephrology 2025, we review mechanisms of kidney injury linked to medicinal plants.
🔗 link.springer.com/chapter/10.1...
#Nephrology #TropicalMedicine #KidneyHealth
Some plants are nephrotoxic and can injure the kidneys.
📖 In Tropical Nephrology 2025, we review mechanisms of kidney injury linked to medicinal plants.
🔗 link.springer.com/chapter/10.1...
#Nephrology #TropicalMedicine #KidneyHealth